UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 7, 2012

Sucampo Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware	001-33609	30-0520478
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
4520 East-West Highway, 3rd Floor Bethesda, Maryland		20814
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (301) 961-3400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01. Regulation FD Disclosure.

On September 7, 2012, Sucampo Pharmaceuticals, Inc. will meet with investors and analysts and make a corporate update presentation at an investor conference in New York City, NY at the 19th Annual NewsMakers in the Biotech Industry Conference being sponsored by BioCentury and Thomson Reuters that will include written communication comprised of slides. The slides from the presentation are being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 to this Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 The corporate update presentation slides dated September 7, 2012.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SUCAMPO PHARMACEUTICALS, INC.

Date: September 7, 2012

By: /s/ Thomas J. Knapp
Name: Thomas J. Knapp
Title: Corporate Secretary

BioCentury Thomson Reuters

NewsMakers 2012 in the BioTech Industry

Ryuji Ueno, MD, PhD, PhD, Chair, CEO, CSO
Cary J. Claiborne, CFO
Stanley G. Miele, SVP, Sales & Marketing
Silvia Taylor, SVP, IR, PR & Corporate Communications
September 7, 2012

Forward-Looking Statements

This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's Form 10-K for the year ended Dec. 31, 2011, which the Company incorporates by reference.

Sucampo Snapshot

A commercial-stage, global biopharmaceutical company since 1996

- **2 FDA-approved drugs based on our proprietary prostone technology**
  - AMITIZA® (lubiprostone) in Gastroenterology market
  - RESCULA® (unoprostone isopropyl) in Ophthalmology market

- **The therapeutic potential of prostones was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' chairman and chief executive officer.** Dr. Ueno and Sachiko Kuno, Ph.D., founded Sucampo Pharmaceuticals in 1996

- **AMITIZA has helped 6 million patients over 6 years** combat the effects of chronic idiopathic constipation and irritable bowel syndrome with constipation

- **New indications for current areas**

- **New global markets and diseases**

- **Deep and promising pipeline**

Second Quarter 2012 and Recent Highlights

AMITIZA®

- Approved in Japan June 2012
- Filed OIC sNDA July 2012

RESCULA®

- US: Anticipate approval of sNDA for glaucoma indication in US (new label/updated MOA)
- EUROPE: Re-approval filings in EU and Switzerland

Research and Development

- Pipeline prioritized

Financial/Corporate

- **Cash, cash equivalents, and investments**
  - Ended Q2 2012 with $89M
- **Revenue**
  - Q2 $16.7M up 19%, 1H $31.1M up 19%
  - 1H 2012 - Net Operating Cash Flow Positive
  - Dual class of Common Stock Eliminated

SUCAMPO PHARMACEUTICALS, INC.

Proprietary Prostone Technology

- **Prostones are naturally occurring compounds that act locally to restore injured cells and tissues**
  - Prostones possess a unique mechanism of action as potent and specific activators of ion channels.
    - Ion channels regulate the flow of specific ions into and out of cells. This regulation is key to the functioning of cells, such as metabolic processes and cell survival
  - There is evidence that prostones have anti-inflammatory properties, prevent cell death, and restore cells and organs
- **Ion channels are ubiquitous in the body, and targeted dosing of prostones may have broad applicability in many degenerative diseases**
- **Sucampo has pioneered the field of prostones**
  - Broad patent estate (>580 issued patents)
  - Developed synthetic analogs of naturally occurring prostones, which are more potent, selective and stable than naturally occurring prostones, enabling their use as drugs
- **The safety profile of prostone compounds is excellent, as demonstrated by the clinical safety record of AMITIZA and RESCULA**

SUCAMPO PHARMACEUTICALS, INC.

Sucampo Is a Leader in Gastroenterology: AMITIZA

Gastroenterology

Areas of Focus: Chronic Idiopathic Constipation (CIC) and Irritable Bowel Syndrome (IBS)

- **CIC**
  - Constipation is characterized by infrequent stools, difficult stool passage, or both[1]
  - CIC affects an estimated 14% of the US adult population (33 million)[2]
  - Constipation accounts for 92,000 hospitalizations in the US each year[3]
  - Studies have found that severe constipation is associated with increased cardiovascular risk in women[4,5]
- **IBS**
  - IBS is defined as abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months[1]
  - IBS affects an estimated 15% of the adult population (45 million)[6]
    - IBS with constipation (IBS-C) affects approx. 5% of the adult population (12 million)[6]
  - Direct and indirect costs of IBS care in the US are estimated at about $20 billion per year[6]
  - Studies have documented that patients with IBS consume more than 50% more health care resources than those without IBS[7]

Source: See References 1-7

Sucampo Is an Emerging Player in Ophthalmology: RESCULA

Ophthalmology

Area of Focus: Glaucoma

- **Glaucoma is a group of ocular diseases with various causes that ultimately are associated with a progressive optic neuropathy leading to loss of vision function[8]**
- **Glaucoma is an age-related disease**
  - Glaucoma is the second leading cause of bilateral blindness worldwide[9]
  - It will affect an estimated 79.6 million people worldwide by 2020[9]
- **As of 2009, 120,000 people in the United States were blind because of glaucoma[10]**
- **An estimated 2.2 million people had the most common form of glaucoma – OAG – expected to increase to 3.36 million in 2020[11]**

Source: See References 8-11

Sucampo's Prostone Technology Has Resulted in Two FDA-Approved Products

AMITIZA® (lubiprostone) for Chronic Idiopathic Constipation (CIC) in adults and Irritable Bowel Syndrome with Constipation (IBS-C) in adult women

- Product Overview
  - AMITIZA is a chloride ion channel activator
  - FDA approved and marketed for CIC in adults and IBS-C in adult women; sNDA for OIC filed July 2012
  - Activation of this channel in cells within the intestinal tract results in fluid secretion and repair of epithelial cell barriers which are essential to the normal function of the digestive track

RESCULA® (unoprostone isopropyl) for the lowering of intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension in patients who are intolerant of or insufficiently responsive to other IOP-lowering medications

- Product Overview
  - RESCULA is a potassium ion channel activator
  - FDA approved for the lowering of intraocular pressure (IOP) in primary open-angle glaucoma and ocular hypertension
  - Activation of this channel relaxes contractile cells, resulting in decreased intraocular pressure which is a known risk factor for glaucoma-associated vision loss

SUCAMPO PHARMACEUTICALS, INC.

Key Facts

Trading Symbol	SCMP
Corporate Headquarters	Bethesda, MD
Stock Price (9-4-2012), 52-Week Range	$4.52, $8.50 to $2.96
Shares Outstanding (9-4-2012)	41.9 M (1 class of common stock)
Daily Volume (90-day average at 9-4-2012)	61,111
Market Capitalization (9-4-2012)	$189 M
Debt (6-30-12)	$60.4 M
Cash (6-30-12)	$88.6 M
Enterprise Value	$188.1M
YTD Total Revenue (6-30-2012)	$31.1 M
Full-time Employees (12-31-2011)	~110
Fiscal Year Ends	December 31
Accounting Firm	PricewaterhouseCoopers, LLP

Management

Ryuji Ueno, M.D., Ph.D., Ph.D., Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-Founder

- R-Tech Ueno, LTD, Co-Founder
- MD and Ph.D. (Medicinal Chemistry) from Keio University; Ph.D. (Pharmacology) from Osaka University

Cary J. Claiborne, Chief Financial Officer

- New Generation Biofuels, CEO, CFO, Director
- Osiris Therapeutics, CFO
- Constellation Energy Group, VP Financial Planning
- Senior leadership positions with General Electric (15 years), MCI and Home Depot

Stanley G. Miele, President, Sucampo Pharma Americas, LLC and Senior Vice President, Sales and Marketing, Sucampo Pharmaceuticals, Inc.

- Abbott Laboratories
- Millennium Pharmaceuticals (COR Therapeutics)

Greg Deener, Senior Vice President, Marketing Strategy and Implementation

- GTx, Inc.
- GlaxoSmithKline

Thomas J. Knapp, Executive Vice President, Chief Legal Officer and Secretary

- NorthWestern Corporation, General Counsel and Corporate Secretary
- Boeing

Other executive experience includes FDA/Center for Drug Evaluation and Research, Procter & Gamble, Pfizer, MedImmune, Allergan, and GlaxoSmithKline

SUCAMPO PHARMACEUTICALS, INC.

Amitiza® (lubiprostone)

AMITIZA® (lubiprostone)

- **Approved in**
  - US for CIC in adults (2006) and IBS-C in adult women (2008)
    - Partnered with Takeda Pharmaceuticals in US
    - Royalty revenue of $41.5 M on net sales of $226.4M in 2011
  - Switzerland for CIC (2009)
    - Limited marketing
  - Japan for chronic constipation (2012)
    - 4Q 2012 launch
    - Partnered with Abbott Japan
- **Filed in**
  - US for OIC (July 2012)
  - UK for CIC (August 2011)
    - Expect UK approval 3Q 2012

- **Sucampo plans to commercialize AMITIZA in Europe**

SUCAMPO PHARMACEUTICALS, INC.

AMITIZA Mechanism of Action
CIC-2 Ion Channel Activation



- **The mucosal barrier within the intestinal tract can be damaged by disease or injury (e.g., IBS) leading to symptomatic manifestations**
- **AMITIZA can help restore tight junctions by binding and activating CIC-2 channels**
- **The CIC-2 chloride channel allows chloride to flow out of cells, promoting fluid secretion**

SUCAMPO PHARMACEUTICALS, INC.

Chronic Constipation and IBS-C are Large Markets with Unmet Medical Needs

Source: See References 2-3 and 12-19

SUCAMPO PHARMACEUTICALS, INC.

New Indication in OIC Will Expand the AMITIZA Franchise

- **Sucampo and Takeda announced filing of sNDA for OIC on July 26, 2012**
  - Seeking approval for a new indication for AMITIZA® (lubiprostone) for the treatment of opioid-induced constipation (OIC) in patients with chronic, non-cancer pain
  - Filing is based on results from three Phase 3, well-controlled studies of 12 weeks' duration in patients taking opioids chronically for non-cancer pain, as well as a long-term, open-label safety study, which provide additional support for use in this population
  - Global trials: 250 sites, 1,500 patients
  - Takeda funded the first $50M and 50% of trial costs in excess of $50 million

- **FDA decision expected 1H13**

A Significant Portion of Opioid Users Develop Opioid-induced Constipation



Source: See References 17-22

SUCAMPO PHARMACEUTICALS, INC.

Amitiza Growth Opportunities

- **Expansion of the AMITIZA franchise**
  - **New geographic markets**
  - **New indications**

- **Growth in United States**
  - Increase CIC and IBS-C sales
    - Patient awareness
    - Customer targeting
    - Managed care access
    - Sales force efforts
  - Approval of sNDA for OIC

- **Growth in Japan and Europe**
  - Recent approval in Japan, partnered with Abbott Japan
  - Expect approval of an MAA for CIC in the UK
  - Anticipate filing for OIC in the UK with other European countries to follow

RESCULA® (unoprostone isopropyl)

RESCULA® (unoprostone isopropyl)

- Approved in
  - US for the lowering of intraocular pressure (IOP) in primary open-angle glaucoma (POAG) and ocular hypertension (OH) in patients who are intolerant of or insufficiently responsive to other IOP-lowering medications (2000)
  - Many European and several South American and Middle Eastern countries for treatment of glaucoma (late 1990's)
  - In Japan for treatment of glaucoma (1994)
- Filings in
  - US to fully reflect current scientific understanding of mechanism of action, approval expected 3Q 2012 (label update)
  - MAAs to be filed in EU and Switzerland by year-end to fully reflect current scientific understanding of mechanism of action
- Licensed worldwide commercialization and development rights (except Japan, Korea, Taiwan and People's Republic of China) from R-Tech Ueno, Ltd. (2010, 2011)
- Sucampo to launch RESCULA in US by the end of 2012
- Will commercialize in Europe

SUCAMPO PHARMACEUTICALS, INC.

BK (Maxi-K) Potassium Channel Activation
RESCULA's Unique Mechanism of Action



- **RESCULA eye drops lower intra-ocular pressure (IOP)**
- **BK channel activation hyperpolarizes the cell and leads to the relaxation of the trabecular meshwork to increase the outflow of aqueous humor**

Source: See References 23-37

US Glaucoma Market Overview

- **The US glaucoma market is 29.2M TRx's[41]**
  - 4-5M potential patients[40,41,43]
  - 67% of the market is generic[42]
  - 80% of TRx's are by eye specialists[42]
  - Limited new products vs. reformulations
- **Compliance and adherence are unmet needs**
  - 50% of new patients drop off therapy within one year of initiation
- **Prostaglandins are inflammatory agents which depolarize cell membranes**
  - #1 reason for discontinuation of prostaglandins is hyperemia[39,43,44]
- **There is opportunity in this market for a differentiated product with a novel mechanism of action, such as Rescula**
- **Glaucoma sales volume (market opportunity):**
  - ~$3B in US (2012)
  - ~$1B in Japan (2011)

Source: See References 38-43

RESCULA Growth Opportunities

- Sucampo is seeking revisions to the label to more accurately reflect current scientific understanding
  - We anticipate agreement on the final RESCULA label during 3Q 2012

- Advantages of RESCULA
  - Reduces IOP throughout the day alone or in combination
  - Avoids side effects seen with other agents
  - Novel MOA: ion channel activator promotes aqueous humor outflow through the trabecular meshwork

- Sucampo plans to launch RESCULA by the end of 2012

Deep and Validated Clinical Pipeline

*Label update in the US and EU; re-launch in US and resubmission in EU and Switzerland **Awaiting results of R-Tech Ueno trial in this indication

Key Value Drivers

- AMITIZA
  - US
    - ✓ Filed OIC sNDA mid-year 2012
    - ✓ Decision in Takeda arbitration resolved dispute
  - Switzerland
    - • **Pricing resolution in 4Q12**
  - Japan
    - ✓ Approved in Japan June 2012
    - • **Await pricing decision in 3Q12**
    - • **Launch in 4Q12**
  - EU
    - • **Expect approval of MAA in UK for CIC in 3Q12**
    - • **Submit OIC MAAs in UK and Switzerland**
- RESCULA
  - US
    - • **Anticipate approval of sNDA for glaucoma indication in US (updated label)**
    - • **Launch in 4Q12**
  - EU
    - • **Re-approval filings in EU and Switzerland**

✓ Completed
• **In process**

SUCAMPO PHARMACEUTICALS, INC.

Appendix

Issued Lubiprostone Patents

US Patent No.	Expires	Type of patent
5,284,858	2014	Composition of matter
6,414,016	2020	Therapeutic use (treating conditions including constipation)
6,583.174	2020	Composition of matter
7,064,148	2022	Therapeutic use (treating conditions including constipation)
7,417,067	2020	Composition of matter
7,795,312	2024	Therapeutic use (treating conditions including IBS)
8,026,393	2027	Formulation
8,071,613	2020	Method for relieving constipation in IBS-C
8,088,934	2021	Composition of matter
8,097,649	2020	Composition of matter
8,097,653	2022	Therapeutic use (treating constipation)
8,114,890	2020	Composition of matter
4,332,316	2020	Composition of matter
4,332,353	2022	Therapeutic use
4,684,334	2021	Therapeutic use (treating conditions including constipation)
4,783,794	2027	Composition of matter
4,786,866	2022	Therapeutic use (treating constipation)

*For Orange Book-listed patents concerning lubiprostone, see for example:
http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021908&Product_No=001&table1=OB_Rx

Issued Lubiprostone Patents

Japanese

Patent No.	Expires	Type of patent
4,332,316	2020	Composition of matter
4,332,353	2022	Therapeutic use
4,684,334	2021	Therapeutic use (treating conditions including constipation)
4,783,794	2027	Composition of matter
4,786,866	2022	Therapeutic use (treating constipation)
4,852,229	2022	Therapeutic use (treating constipation)
4,889,219	2023	Therapeutic use (treating constipation)

European

Patent No.	Expires	Type of Patent
1,220,849	2020	Composition of matter
1,315,485	2021	Therapeutic use (treating constipation)
1,392,318	2022	Therapeutic use
1,426,361	2020	Composition of matter
1,443,938	2022	Therapeutic use (treating constipation)

*For Orange Book-listed patents concerning lubiprostone, see for example:
http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021908&Product_No=001&table1=OB_Rx

SUCAMPO PHARMACEUTICALS, INC.

References

1. American College of Gastroenterology
2. Suares et al. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106:1582-1591.
3. Lembo et al. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 9th ed. Philadelphia, PA: Elsevier Saunders. 2010; 259-284.
4. Salmoirago-Blotcher et al. Constipation and risk of cardiovascular disease among postmenopausal women. Am J Med. 2011; 124:714-723.
5. Talley NJ, et al. Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life. Am J Gastroenterol. 2001;96:71-76.
6. Saito YA, et al. The epide-miology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol. 2002;97:1910-1915.
7. Hulisz D. The burden of illness of irritable bowel syndrome: current challenges and hope for the future. J Manag Care Pharm. 2004 Jul-Aug;10(4):299-309.
8. Fingeret, AOA Optometric Clin Pract Guideline, 2011
9. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. *Br J Opthalmol.* 2006; 90: 262-267
10. Glaucoma Research Foundation. Glaucoma facts and stats. http://www.glaucoma.org. Updated January 12, 2009
11. Friedman DS. Prevalence of open angle glaucoma among adults in the United States. *Arch Ophthalmol.* 2004; 122: 532-538
12. Kantar Health Epi database http://epidb.khapps.jp/ (per Abbott Japan).
13. Kubo. et al. (2010) Differences between risk factors among irritable bowel syndrome subtypes in Japanese adults 23, 249-254.
14. Muller-Lissner, S. et al. (2001) Epidemiological Aspects of Irritable Bowel Syndrome in Europe and North America. Digestion, 64, 200-204.
15. Chey, W. et al "Frequency and Bothersomeness of Symptoms, Health Care Seeking Behavior and Satisfaction with Therapy in IBS-C Patients Meeting ROME II Criteria: Results of a Population Based Survey."

SUCAMPO PHARMACEUTICALS, INC.

References Cont.

16. Schoenfield, P. "System Frequency, Health Care Seeking Behavior, and Satisfaction with Therapy among Chronic Constipation Patients: Results of a Population-Based Survey".
17. US population statistics based on data from http://www.census.gov/compendia/statab/cats/population.html and http://quickfacts.census.gov/qfd/states/00000.html accessed July 2012.
18. Japanese population statistics based on data from http://www.indexmundi.com/g/g.aspx?c=ja&v=21 and http://www.ipss.go.jp/webj-ad/WebJournal.files/population/2012_Vol.10/Web%20Journal_Vol.10_02.pdf accessed July 2012.
19. European population statistics based on data from http://epp.eurostat.ec.europa.eu/portal/page/portal/statistics/search_database accessed July 2012.
20. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Clinical and Systematic Reviews. 2011; 106: 835-842.
21. Breivik et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006 May;10(4):287-333
22. Hess et al. Attitude of Swiss physicians towards opioid-induced constipation: a national survey. Eur J Intern Med. 2011 Oct;22(5):527-31.
23. Yu DY et al. Invest Ophthalmol Vis Sci. 1994;35:4087-4099.
24. Kern TS. Exp Diabetes Res. 2007;2007:95013.
25. Hardy P et al. Prostaglandins Leukot Essent Fatty Acids. 2005;72(5):301-325.
26. Alm A et al. Exp Eye Res. 2009;88:760-768.
27. Toris CB et al. Arch Ophthalmol. 2004;122:1782-1787.
28. Llobet A et al. News Physiol Sci. 2003;18:205-209.
29. Kojima S et al. Nippon Ganka Bakkai Zasshi. 1997:101;605-610.
30. Makimoto Y et al. Jpn J Ophthalmol. 2002;46:31-35.
31. Kimura I et al. Jpn J Ophthalmol. 2005;49:287-293.

SUCAMPO PHARMACEUTICALS, INC.

References Cont.

32. Sugiyama T et al. Arch Ophthalmol. 2009;127:454-459.
33. Inoue K et al. Clinical Ophthalmology 2011:5 1003-1005.
34. Hayami K et al. Ophthalmic Res. 2001 Jul-Aug;33(4):203-9.
35. Melamed S. Drugs Exp Clin Res 2002;28(2-3):63-73.
36. Ishida T al. Topical Monotherapy for Normal Tension Glaucoma-Comparison of Long-term Monotherapies in Maintaining Visual Field. Ophthalmology 47:1107-1112,2005.
37. ARVO 2011, Poster#4992,A416.
38. American Academy of Ophthalmology.
39. Friedman et al. Prevalence of Open-Angle Glaucoma Among Adults in the United States. Arch Ophthalmol. 2004 Apr;122(4):532-8.
40. July 2011-June 2012 MATTY IMS NPS data.
41. July 2011-June 2012 MATTY IMS NPA data.
42. Catalina presentation 2011.
43. Input from KOLs.

SUCAMPO PHARMACEUTICALS, INC.

SUCAMPO PHARMACEUTICALS, INC.

BioCentury
Thomson Reuters

NewsMakers 2012 in the BioTech Industry

Ryuji Ueno, MD, PhD, PhD, Chair and CEO
Cary J. Claiborne, CFO
Stanley G. Miele, SVP, Sales & Marketing
Silvia Taylor, SVP, IR, PR & Corporate Communications
September 7, 2012